NCT06854952CompletedPhase 2
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 167 (actual)
- First submitted
- 25 Feb 2025
- Start date
- 7 Mar 2025
- Primary completion date
- 19 Aug 2025
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Diseases
- Obesity
- NCT number
- NCT06854952
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 167
- From 7 Mar 2025 to the primary completion date, 19 Aug 2025
- 17 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have had or are planning surgical treatment or device-based therapy for obesity
Other illness
- Have diabetes mellitus
- Have obesity induced by medication or other diagnosed endocrinologic disorders
- Lifetime history of suicide attempt
Who the study is looking for
- Female or male aged 18 to 75 years
- Body mass index (BMI) of:
- ≥ 30 kg/m\^2 to \< 50 kg/m\^2
- OR
- ≥ 27 kg/m\^2 to \< 30 kg/m\^2 with at least 1 weight-related comorbidity
- HbA1c \< 6.5%
- Stable self-reported body weight for at least 3 months prior to study (\< 5% body weight gain or loss)
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (17)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
- Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.Obesity (Silver Spring) · 2026 · PMID 42528333
This page is information, not medical advice. Discuss any trial with your doctor.